Trials / Active Not Recruiting
Active Not RecruitingNCT05215067
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
A Phase II Trial of AK104 in Combination With Docetaxel in Subjects With Advanced Non-Small Cell Lung Cancer and Progressive Disease After Platinum Doublet Chemotherapy and Treatment With One Prior Anti-PD-1/PD-L1 Monoclonal Antibody (mAb)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) combined with Docetaxel in Advanced Non-Small Cell Lung Cancer whose disease has progressed after prior platinum doublet chemotherapy and anti-PD-1/PD-L1 monoclonal antibody
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | IV infusion,Specified dose on specified days |
| DRUG | Docetaxel | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2022-03-09
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2022-01-31
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05215067. Inclusion in this directory is not an endorsement.